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Background. Optimal use of angiotensin-converting enzyme inhibitors (ACEIs) is crucial to improve the treatment outcome in heart
failure patients. However, little is known about the optimal use of ACEIs among heart failure patients in our setting. Therefore, our
study aimed to investigate the utilization and optimal dosing of ACEIs and associated factors in heart failure patients. Method.
A cross-sectional study was conducted on randomly selected patients with heart failure between February 2016 and June 2016 at
ambulatory care clinic of Jimma University Medical Center, Ethiopia. Data were collected through patient interview and review of
medical records. Binary logistic regression analysis was done to identify factors associated with utilization and optimal dosing of
ACEIs. Results. A total of 308 patients were included in the final analysis of this study. The mean (±standard deviation) age of the
patients was 52.3 ±15.5 years. Out of the total, 74.7% of the patients were receiving ACEIs. Among the patients who were receiving
ACEIs, only 35.7% were taking optimal dose. New York Heart Association (NYHA) class III (Adjusted odds ratio (AOR):0.12, 95%
confidence interval (CI):0.02–0.98), valvular heart disease (AOR: 0.27, 95% CI: 0.13-0.56), hypertension (AOR: 5.82, 95% CI: 2.16-
15.71), and diabetes mellitus (AOR: 3.84, 95% CI: 1.07-13.86) were significantly associated with the use of ACEIs, whereas age ≥65
(AOR: 2.61, 95%CI: 1.20-5.64), previous hospitalization for heart failure (AOR: 2.08, 95%CI: 1.11-3.92), diuretic use (AOR: 5.60,
95%CI: 2.75-11.40), and dose of furosemide >40mg (AOR: 9.80, 95%CI: 3.00-31.98) were predictors of suboptimal dosing of ACEIs.
Conclusion. Although majority of patients were receiving ACEIs, only about one-third were using optimal dosage. Valvular heart
disease andNYHA class III were negatively associatedwith the use of ACEIs while previous hospitalization for heart failure, old age,
diuretic use, and diuretic dose were predictors of suboptimal dosing of ACEIs. Therefore, more effort needs to be done tominimize
the potentially modifiable risk factors of suboptimal use of ACEIs therapy in heart failure patients.
1. Introduction
Heart failure (HF) is a global public health threat that
affects about 26 million people worldwide [1]. Currently, HF
becomes one of the most important public health concerns in
developing countries including sub-Saharan Africa [2, 3]. HF
is a debilitating illness that is associated with a high burden
of morbidity and mortality, impaired quality of life, and
increased health care expenditure [1–3]. Despite the major
therapeutic advances that have occurred in the management
of HF patients over the past decades, HF remains the leading
cause of morbidity, mortality, and economic burden for
health care budgets [4].
Studies have shown that the implementation of evidence-
based guideline-recommended drug treatments for HF has
resulted in the reduction of HF associated morbidity and
mortality [4, 5]. However, HF remains a substantial con-
tributor of morbidity and mortality due to the complexity
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of multiple comorbidities, polypharmacy, advanced age, and
lack of implementation of recommended medications or
proper titration of these drugs [4, 5].
Angiotensin-converting enzyme inhibitors (ACEIs) are
the cornerstone of standard HF therapy. In absence of
contraindication, ACEIs should be prescribed for all patients
with systolic HF [6, 7]. However, they are often underuti-
lized in a real clinical practice [8, 9]. ACEIs have been
proved to have mortality and morbidity benefits in patients
with systolic HF in several clinical trials [10–13]. In HF
patients with reduced ejection fraction, ACEIs therapy leads
to symptomatic improvement, reduced hospitalization, and
enhanced survival [10, 14].
The clinical benefits of ACEIs in HF patients appear
to be dose-dependent and a better benefit has occurred at
higher target doses [15, 16]. ACEI uptitration to a maximum
tolerable dose is important in chronic HF patients to reduce
the incidence of hospitalization, morbidity, and mortality
as well as improve the quality of life of the patients [17–
19]. Several studies indicated that a target dose of ACEI is
achievable in the majority of chronic HF patients and the
achieved optimal dose was associated with better treatment
outcomes [4, 14, 17, 18]. Therefore, every effort should be
made to achieve the target dose or maximum tolerable dose
to get the maximum clinical benefit [6, 7].
According to the evidence-based guidelines [6, 7], the
recommended daily target doses of ACEIs are 20–40 mg
enalapril, 10mgRamipril, 150mg captopril, 20–40mg Lisino-
pril, 40mg fosinopril, 4mg trandolapril, 40 mg quinapril,
or 8-16 mg perindopril. Although evidence-based guidelines
recommend the use of the target doses used in clinical trial for
the treatment of HF patients [20, 21], attaining target doses
is often challenging in daily practice owing to the multiple
comorbidities, polypharmacy, and side effects particularly in
older individuals [22]. Generally, ACEIs are prescribed in
doses lower than the target doses that have been shown to
reducemorbidity andmortality in patients withHF in clinical
trials [9, 19].
The target doses of ACEIs are tolerable in the majority
(>80%) of HF patients if titrated appropriately [17, 21, 23].
However, several studies reported that substantial number
of patients were receiving below the target doses of ACEIs
[15, 22, 24]. More importantly, underutilization and sub-
optimal dosing of ACE inhibitors limit the morbidity and
mortality benefit for HF patients [18, 19]. To our knowledge,
however, the optimal use of ACEIs has not been investigated
yet in our healthcare settings. Hence, our study investi-
gated the optimization of ACEIs therapy and associated
factors in the management of ambulatory patients with
HF.
2. Material and Methods
2.1. Study Design and Study Setting. A hospital-based cross-
sectional study was conducted from February 2016 to June
2016 at ambulatory care clinic of Jimma University Medical
Center, which is the major public hospital in southwest
Ethiopia with a catchment population of about 15 million
people.
2.2. Study Population and Data Collection Procedure. Adult
patients (age ≥18 years) with a diagnosis of HF and a baseline
ejection fraction <40% confirmed by Echocardiogram and
thosewho had been on regular follow-up for at least 6months
were included in the study. Patients with precautions and
contraindications to the use of ACE inhibitors including
pregnancy, history of angioedema, allergic reaction to the
drug, dry cough, hyperkalemia (> 5.5mEq/mL), hypotension
(<90/60mmg), renal insufficiency (creatinine clearance <30
mL/ min), aortic or mitral stenosis, and bilateral renal artery
stenosis and those patients with incomplete medical record
were excluded from the study.
A sample of 340 was calculated using a single popula-
tion proportion formula assuming 50% proportion of ACE
inhibitor utilization and dose optimization among patients
with HF, 95% confidence level, 5% margin of error, and 10%
of contingency for nonresponse rate. From a total of 340
participants approached, 32 patients were excluded from the
study due to contraindication to ACEIs [25] and incomplete
medical record [7]. Patients were recruited randomly into the
study during their appointment formedication refilling. Data
concerning sociodemographic were retrieved by interview-
ing patients using the standardized questionnaire. The clini-
cal and treatment related characteristics were retrieved from
patients’ medical record using data abstraction checklist.
We determined the utilization and dose of ACEIs. ACEIs
were said to be underutilized if they were not used by the
patients in absence of contraindications. The optimal dosing
of ACEISs was determined according to the evidence-based
guideline-recommended target doses [21]. Accordingly, the
dose of ACEIs was said to be optimal if it was given at
guideline-recommended target dose or a maximum tolerable
dose is given for the patients. For enalapril, the optimal dose
was considered if the dose was ≥20 mg daily or a maximum
tolerable dose and for captopril, the dose was said to be
optimal if it was ≥150 mg daily or a maximum tolerable dose,
whereas the dose was said to be suboptimal if the patient was
taking any dose of ACEIs below the target dose in absence of
contraindications for uptitration.
2.3. Data Analysis. EPI data management (version 4.2.0) and
the Statistical Package for the Social Science (SPSS version
21.0) were used to record and analyze the data, respectively.
Descriptive analysis was computed using frequency for cat-
egorical variables. Moreover, the mean (standard deviation)
and median (interquartile) were computed for continuous
variables. Multicollinearity was checked to test correlation
among independent variables using variance inflation fac-
tor and none was collinear. Univariable logistic regression
analysis was performed to determine the association of each
independent variable with utilization and dose optimization
ofACEIs, and then independent variables with p value<0.2 in
univariable analysis were included in themultivariable binary
logistic regression model to identify predictors of treatment
optimization of ACEIs. A p value of <0.05 was considered
statistically significant in all analyses.
2.4. Ethics Approval and Consent to Participate. Approval for
this study was obtained from institutional review board of
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Table 1: Sociodemographic related characteristics of HF patients
(n=308).
Characteristics n (%)
Sex, male 157 (51)
Age in years
<65 227 (73.7)
≥65 81 (26.3)
Residence, rural 192 (63.3)
Educational level
Unable to write and read 174 (56.5)
Primary education 52 (19.6)
Secondary education 26 (8.4)
College and above 56 (18.2)
Marital status
Married 233 (75.6)
Single 3 (9.7)
Divorced 19 (6.2)
Widowed 26 (8.4)
Jimma University, College of Health and Medical Sciences.
The aim and protocol of the study were fully explained to all
study participants included in the study andwritten informed
consent was obtained from each participant. The personal
information was entirely confidential and protected. All
methods were performed in accordance with the approved
institutional guidelines.
3. Results
3.1. Sociodemographic and Clinical Characteristics. A total
of 308 patients were included in this study. The mean [±
standard deviation (SD)] age of the patients was 52.3±15.5
years and 51.5% were males. The majority (63.3%) of the
patients were rural dwellers and more than half (56.5%) were
unable to write and read (Table 1).
3.2. Clinical and Medication-Related Characteristics. More
than half (57.1%) of the patients had been hospitalized one or
more times in the preceding one year.Themajority of patients
were in NYHA class III (48.4%) and II (44.5%). Almost two-
thirds (62.7%) of the patients had two or more comorbidities
and the most commonly identified comorbidity was ischemic
heart disease (45.1%) followed by hypertension (26.9%) and
valvular heart disease (21.4%). The mean (±SD) number
of medications per patient was 4.2±1.2 and 43.5% of the
patients were taking five more medications. Among the HF
medications, the most frequently used medications were
loop diuretics (78.9%) followed by ACEIs (74.7%) and beta-
blockers (61 .4%) (Table 2).
3.3. Utilization andDosing ofACEIs inHFPatients. Out of the
total, 230 (74.7%) patients were receiving ACEIs. Enalapril
(93.5%) and captopril (6.5%)were the only prescribed ACEIs.
Among the patients who were receiving ACEIs, only 82
(35.7%) were taking optimal dose. Overall, almost three-
fourths (73.4%) of the patients were either not receiving
Table 2: Clinical and medication related characteristics of HF
patients (n=308).
Characteristics n (%)
Previous hospitalization
no 132 (42.9)
Yes 176 (57.1)
Duration
<2 108 (35.1)
>=2 200 (64.9)
NYHA class
I 22 (7.1)
II 137 (44.5)
III 149 (48.4)
Frequently identified comorbidities
Ischemic heart disease 139 (45.1)
Hypertension 83 (26.9)
Valvular heart diseases 66 (21.4)
Atrial fibrillation 64 (20.8)
Diabetes mellitus 52 (16.9)
Hyperthyroidism. 22 (7.1)
Chronic kidney disease 17 (5.5)
Number of comorbidities
<2 115 (37.3)
≥2 193 (62.7)
Number of medications 157 (51)
<5 174 (56.5)
≥5 144 (43.5)
Commonly used medications
Loop diuretics 240 (78.9)
ACEIs 230 (74.7)
Beta-blockers 189 (61.4)
ACEIs + Beta-blockers 180 (58.4)
Antiplatelets 187 (60.7)
Statins 134 (43.5)
Potassium sparing diuretics 68 (22.1)
Cardiac glycosides 58 (18.8)
ACEIs, angiotensin converting enzyme inhibitors; NYHA, New York Heart
Association.
ACEIs or receiving a suboptimal dose. The mean daily doses
of enalapril and captopril that were taken byHF patients were
12 mg and 55 mg, respectively (Table 3).
3.4. Factors Associated with the Use of ACEIs. Univariable
logistic regression analysis was performed to compare HF
patients who were taking ACEIs and not taking ACEIs using
the sociodemographic, clinical, and treatment related charac-
teristic. Accordingly, NYHA class III (P=0.047) and valvular
heart disease (P=0.001) were negatively associated with the
use of ACEIs while hypertension (P=0.001) and diabetes
mellitus (P=0.040) were positively associated. Moreover,
variables with P<0.2 in the univariable were reentered into
the multivariable logistic regression model.The whole model
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Table 3: Type and dose of ACEIs used in HF patients (n=230).
Variables Medications
Enalapril Captopril
Number of patients on the medication (%) 215 (93.5) 15 (6.5)
Number of patients on the optimal dose (%) 81 (37.7) 1 (6.7)
Number of patients on 50 to <100% of the target dose (%) 25 (11.6) 5 (33.3)
Number of patients on <50% of the target dose (%) 109 (50.7) 9 (60)
Mean (SD) daily dose (mg/d) 12 (8.3) 55 (33.6)
Median (IQR) dose received (mg) 7.5 (5-20) 37.5 (37.5-75)
Minimum dose used (mg/d) 2.5 18.75
Maximum dose used (mg/d) 40 150
SD, standard deviation; IQR, interquartile.
Table 4: Factors associated with the utilization of ACEIs (n=308).
Variables ACEIs use COR (95% CI) p-value AOR (95%CI) p-value
No, n (%) Yes, n (%)
Age category
<65 62 (79.5) 165 (71.7) 1 1 1 1
>=65 16 (20.5) 65 (28.3) 1.53 (0.82-2.84) 0.181 1.02 (0.47-2.19) 0.964
Hospitalization in the last one year
No 39 (50.0) 93 (40.4) 1 1 1 1
Yes 39 (50.0) 137 (59.6) 1.47 (0.88-2.47) 0.141 1.33 (0.69-2.55) 0.394
Number of comorbidities
<2 36 (46.2) 79 (34.3) 1 1 1 1
>=2 42 (53.8) 151 (65.7) 1.64 (0.97-2.76) 0.064 1.02 (0.51-2.01) 0.964
NYHA class .
I 3 (3.75) 19 (8.3) 1 1 1 1
II 12 (15) 125 (54.8) 0.47 (0.10-2.15) 0.331 1.11 (0.13-9.55) 0.925
III 65 (81.3) 84 (36.8) 0.19 (0.04-0.83) 0.027 0.12 (0.02-0.98) 0.047
Ischemic heart disease
No 48 (61.5) 121 (52.6) 1 1 1 1
Yes 30 (38.5) 109 (47.4) 1.44 (0.85-2.44) 0.172 1.23 (0.60-2.51) 0.579
Hypertension
No 72 (92.3) 153 (66.5)
Yes 6 (7.7) 77 (33.5) 6.04 (2.51-14.51) P<0.001 5.82 (2.16-15.71 0.001
Valvular heart disease
No 42 (53.8) 199 (86.5) 1 1 1 1
Yes 36 (46.2) 31 (13.5) 0.18 (.10-0.32) P<0.001 0.27 (0.13-0.56) 0.001
Diabetes mellitus
No 75 (96.2) 181 (78.7) 1 1 1 1
Yes 3 (3.8) 49 (21.3) 5.91 (1.78-19.63) 0.004 3.84 (1.07-13.86) 0.040
NYHA, New York Heart Association, ACEIs, angiotensin converting enzyme inhibitors, COR, crude odds ratio, AOR, adjusted odds ratio, and CI, confidence
interval.
containing all predictors was statistically significant (Chi-
square = 105.057, df = 9, P<0.001). According tomultivariable
logistic regression analyses, NYHA class III (Adjusted odds
ratio (AOR):0.12, 95% confidence interval (CI):0.02–0.98),
valvular heart disease (AOR: 0.27, 95% CI: 0.13-0.56) hyper-
tension (AOR: 5.82, 95%CI: 2.16-15.71), and diabetes mellitus
(AOR: 3.84, 95% CI: 1.07-13.86) were significantly associated
with the use of ACEIs (Table 4).
3.5. Factors Associated with Dose Optimization of ACEIs.
Factors associated with optimal dosing of ACEIs were also
identified using univariable and multivariable regression
model. The whole model containing all predictors was sta-
tistically significant (Chi-square = 57.059, df = 7, P<0.001).
Age ≥ (AOR: 2.61, 95%CI:1.20-5.64), previous hospitalization
for HF (AOR: 2.08, 95%CI: 1.11-3.92), diuretic use (AOR:
5.60, 95%CI: 2.75-11.40), and dose of furosemide >40 mg
BioMed Research International 5
Table 5: Factors associated with optimal dosing of ACEIs (n=230).
Variables ACEIs dose COR (95% CI) p-value AOR (95%CI) p-value
Optimal, n (%) Suboptimal, n (%)
Age category
<65 69 (84.1) 97 (65.5) 1 1 1 1
≥65 13 (15.9) 51 (34.5) 2.79 (1.41-5.52) 0.003 2.61 (1.20-5.64) 0.015
Hospitalization in the last one year
No 48 (58.5) 46 (31.1) 1 1 1 1
Yes 34 (41.5) 102 (68.9) 3.13 (1.79-5.48) P<0.001 2.08 (1.11-3.92) 0.024
NYHA class
I 10 (12.2) 11 (7.4) 1 1 1 1
II 48 (58.5) 77 (52) 1.51 (0.58-3.92) 0.40 1.70 (0.54-4.87) 0.395
III 24 (29.3) 60 (40.5) 2.59 (0.97-6.93) 0.057 2.27 (0.72-7.19) 0.163
Number of comorbidities
<2 40 (48.8) 39 (26.4) 1 1 1 1
>=2 42 (51.2) 109 (73.6) 2.90 (1.64-5.11) P<0.001 1.85 (0.96-3.60) 0.068
Valvular heart disease .
No 67 (81.7) 132 (89.2) 1 1 1 1
Yes 15 (18.3) 16 (10.8 0.50 (0.23-1.09) 0.082 0.54 (0.22-1.33) 0.180
Diuretic use
No 37 (45.1) 1 1 1 1
Yes 45 (54.9) 5.94 (3.08-11.46) P<0.001 5.60 (2.75-11.40) P<0.001
Dose of furosemide
≤40 mg 40 (89) 79 (60.8)
>40 mg 5 (11) 51 (39.2) 5.17 (1.91-14.0) 0.001 9.80 (3.00-31.98) P<0.001
NYHA, New York Heart Association, ACEIs, angiotensin converting enzyme inhibitors, COR, crude odds ratio, AOR, adjusted odds ratio, and CI, confidence
interval.
(AOR:9.80, 95%CI:3.00-31.98) were significantly associated
with suboptimal dose of ACEIs (Table 5).
4. Discussion
Despite multiple drug therapies, HF remains the leading
cause of morbidity and mortality [4]. Optimization of HF
therapy results in a significant reduction of morbidity and
mortality associated with HF [25, 26]. Assessment of treat-
ment optimization of ACEIs is crucial to provide important
information for clinicians working in the management of
chronic HF. Therefore, our study determined the utilization
and dose optimization of ACEIs and associated factors
among patients with HF. Accordingly, ACEIs were either
underutilized or under-dosed in the majority (73.4%) of the
HF patients.
In agreement with Palestine study [9], the majority of
the patients were either not receiving ACEIs or not receiving
optimal dose of ACEIs in absence of contraindication to the
use or to increase the dose to optimal dose. The use of ACEIs
in systolic HF conferred a 16-20 % reduction in mortality
[27]. Although evidence-based guidelines recommend the
use of ACEIs in all patients with systolic HF [6, 7, 21], about
one-fourth of the patients were not receiving ACEIs without
known reason in our study. Consistent with our finding,
ACEIs were often underutilized in other similar studies [5,
8, 9, 28].
The use of ACEIs was negatively associated with NYHA
class III in our study which was also supported by other
study [21]. The presence of valvular heart disease was
also negatively associated with the use of ACEIs. This
could be due to the controversial indication of ACEIs in
valvular heart disease [29, 30]. Patients with hypertension
were more likely to use ACEIs which was in line with
Palestine study [9]. In addition, the presence of diabetes
mellitus was positively associated with the use of ACEIs.
The possible justification for the positive association of
hypertension and diabetes mellitus with the use of ACEIs
might be due to the additional indication and renoprotec-
tive effect of ACEIs in hypertension and diabetes mellitus
[31].
Studies have demonstrated a dose-related clinical benefit
of ACEI therapy in HF patients [32] and a higher dose
was associated with a better treatment outcome [22]. Hence,
evidence-based guidelines recommend uptitration of ACEIs
to a target dose unless there is tolerability problem [6, 7,
21]. In contrast, almost two-thirds (64.7%) of patients were
on suboptimal dose of ACEIs in this study. This could
be attributed to the absence of heart HF guideline in our
setup.
In agreement with our study, the majority of the patients
were below the target dose in other similar studies [5, 15, 33,
34]. In contrast, our finding was quite different from a study
in Germen [35] in which 62% of the ACEIs doses were at
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the guideline-recommended target dose.Thismight be due to
the difference inmedical practitioners’ expertise and the poor
awareness of dose titration practice of ACEIs as observed in
this study.
In the present study, suboptimal dosing of ACEIs was
significantly associatedwith previous hospitalizationwhich is
in line with other similar studies [18, 32]. Older patients (Age
≥65) were more likely to receive a suboptimal dose of ACEI
compared to their counterparts (age<65). However, studies
have revealed that optimal dose of ACEIs is associated with
reduced all-cause five-year mortality in very old patients with
systolic HF [13]. Despite optimal dose is achievable in the
majority older patients withHF [13], 80% of the older patients
were receiving a suboptimal dose of ACEIs in the present
study.This could be explained that medical practitioners may
fail to prescribe high dose of ACEIs for older patients due to
fear of intolerance.
Appropriate use of diuretics affects the success of other
medications given for the treatment of HF. Studies have
shown that the use of diuretics increased with age and the
increased use of diuretics was associated with a decrease in
the use of the recommended HF drugs including ACEIs and
beta-blockers [36]. More importantly, high dose of diuretics
usually limits the uptitration of drugs that have survival ben-
efit in HF patients including ACEI [37]. Consistent with this,
the diuretic use and dose of furosemide were significantly
associated with the suboptimal dose of ACEIs. This could
be explained that excessive diuresis can increase the risk of
hypotension and renal insufficiency with ACE inhibitors due
to volume depletion [37, 38]. Therefore, clinicians should
prescribe diuretics with careful consideration taking into
account their negative effect on uptitration of other drugs.
Particularly, the dose of diuretics needs to optimized to allow
titration of ACEIs to target dose.
Our study has some limitations. The cross-sectional
nature of our study may not provide adequate evidence of
causality regarding the suboptimal use of ACEIs and its
contributing factors. Our study should be extrapolated to
other countries with caution as the finding of this study
depends on the difference in population demographics,
disease distribution, clinician’s expertise, and the health care
system.
5. Conclusion
Although majority of patients were receiving ACEIs, only
about one-third were using optimal dosage. While hyper-
tension and diabetes mellitus were positively associated with
the use of ACEI, the presence of valvular heart disease and
NYHA class III were negatively associated. Moreover, previ-
ous hospitalization forHF, old age, diuretic use, and dosewere
significantly associated with suboptimal dosing of ACEIs.
We suggest the implementation of multidisciplinary team
approach including clinical pharmacists in the medication
review and patient monitoring process at ambulatory care
clinics for the optimization of ACEIs and achieving definite
outcomes in patients with HF. In addition, more efforts need
to be made to minimize potentially modifiable risk factors of
suboptimal use of ACEIs in HF patients.
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